Neupro® 4 mg/24 h transdermales Pflaster Neupro® 6 mg/24 h transdermales Pflaster Neupro® 8 mg/24 h transdermales Pflaster
Neupro® 4 mg/24 h transdermales Pflaster Neupro® 6 mg/24 h transdermales Pflaster Neupro® 8 mg/24 h transdermales Pflaster
![EP3854388A1 - Transdermal therapeutic system comprising rotigotine and at least one non-amine-resistant silicone adhesive - Google Patents EP3854388A1 - Transdermal therapeutic system comprising rotigotine and at least one non-amine-resistant silicone adhesive - Google Patents](https://patentimages.storage.googleapis.com/01/7e/c9/9f0fa3aa9bec67/imgb0001.png)
EP3854388A1 - Transdermal therapeutic system comprising rotigotine and at least one non-amine-resistant silicone adhesive - Google Patents
![BioNxt gewinnt Kunden: Bahnbrechendes Urteil in den USA macht Weg für Rotigotin-Pflaster frei - Synergien erwartet BioNxt gewinnt Kunden: Bahnbrechendes Urteil in den USA macht Weg für Rotigotin-Pflaster frei - Synergien erwartet](https://assets.wallstreet-online.de/_media/12815/2023/04/25/size_222_182/bionext.png)